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REPORT
Recurrent Mutation in the First Zinc Finger of the Orphan
Nuclear Receptor NR2E3 Causes Autosomal Dominant Retinitis
Pigmentosa
Frauke Coppieters,* Bart P. Leroy,* Diane Beysen, Jan Hellemans, Karolien De Bosscher,
Guy Haegeman, Kirsten Robberecht, Wim Wuyts, Paul J. Coucke, and Elfride De Baere
“Autosomal dominant retinitis pigmentosa” (adRP) refers to a genetically heterogeneous group of retinal dystrophies, in
which 54% of all cases can be attributed to 17 disease loci. Here, we describe the localization and identification of the
photoreceptor cell-specific nuclear receptor gene NR2E3 as a novel disease locus and gene for adRP. A heterozygous
mutation c.166GrA (p.Gly56Arg) was identified in the first zinc finger of NR2E3 in a large Belgian family affected with
adRP. Overall, this missense mutation was found in 3 families affected with adRP among 87 unrelated families with
potentially dominant retinal dystrophies (3.4%), of which 47 were affected with RP (6.4%). Interestingly, affected members
of these families display a novel recognizable NR2E3-related clinical subtype of adRP. Other mutations of NR2E3 have
previously been shown to cause autosomal recessive enhanced S-cone syndrome, a specific retinal phenotype. We propose
a different pathogenetic mechanism for these distinct dominant and recessive phenotypes, which may be attributed to
the dual key role of NR2E3 in the regulation of photoreceptor-specific genes during rod development and maintenance.
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Retinitis pigmentosa (RP [MIM 268000]), a group of retinal
dystrophies, is clinically characterized by early-onset night
blindness, followed by progressive constriction of the pe-
ripheral visual field and, eventually, loss of central vision
in a majority of cases.1 RP is a genetically heterogeneous
monogenic disorder, with 17 autosomal dominant, 25 au-
tosomal recessive and 6 X-linked recessive loci (RetNet,
the Retinal Information Network).
Autosomal dominant RP (adRP) accounts for 20%–40%
of all RP cases. Until now, only 54% of the adRP cases
could be attributed to 17 known loci, of which 15 genes
are known. Overall, both founder mutations as well as
allelic heterogeneity are seen.2 Most of the adRP disease
genes are either expressed preferentially in the photore-
ceptors or the retinal pigment epithelium and encode di-
verse proteins involved in the phototransduction cascade,
retinoid cycle, photoreceptor structure, or transcription
(RetNet).
In this study, a four-generation Belgian family (F1) was
ascertained in which adRP segregates in 25 individuals (fig.
1A). After informed consent was given, genomic DNA was
obtained from 24 affected and 26 unaffected individuals.
As a first step, 15 adRP loci, known at the onset of the
study, were excluded, implicating the involvement of a
novel adRP locus. Subsequently, a genomewide screen was
performed on 23 individuals (ABI Prism Linkage Map-
ping Set, MD-10 v2.5 [Applied Biosystems]) (fig. 1A). Two-
point LOD scores between the disease phenotype and
each of the markers were calculated (SuperLink v1.4,
EasyLINKAGE Plus v4.01beta),3 under the assumption of
a dominant mode of inheritance with a penetrance of
98%, a phenocopy rate of 0.1%, and a disease-allele fre-
quency of 0.0001. Significant linkage was obtained for two
markers on chromosome 15, of which D15S131 yielded
the higher LOD score (5.10 at ) (data not shown).vp 0.00
Segregation analysis of 10 additional flanking microsat-
ellite markers in all available family members revealed crit-
ical recombination events between D15S988 and D15S216
at the proximal end, and between D15S188 and D15S1023
at the distal end. This defined a candidate region of 7.79
cM on 15q22–15q25, containing 172 genes (fig. 1B and
table 1). Two of these—the Bardet-Biedl syndrome-4 gene
(BBS4 [MIM 600374]) and the photoreceptor cell-specific
nuclear receptor gene NR2E3—have a retinal expression
pattern and are involved in retinal biology and disease.
Mutations in BBS4 are known to cause Bardet-Biedl syn-
drome, an autosomal recessive disease characterized by
pigmentary retinopathy and other systemic features.4 Mu-
tations in the NR2E3 gene have been described elsewhere
as causing enhanced S-cone syndrome (ESCS), an auto-
somal recessive retinopathy.5 Moreover, NR2E3 is a key
player in the retinal transcriptional network, with a dual
regulatory role in the terminal differentiation and in the
maintenance of the rod phenotype.6,7
Hence, mutation screening of NR2E3 was performed in
the proband of F1, revealing a novel heterozygous tran-
Figure 1. A, Pedigree of F1, in which NR2E3 mutation p.Gly56Arg was found. WTp wild type; Mp mutation p.Gly56Arg. B, Haplotypes
of critical recombinants of F1 used to narrow candidate region. C, Sequence electropherogram of heterozygous substitution c.166GrA
(p.Gly56Arg) versus wild type. D and E, Pedigrees of F2 and F3, respectively.
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Table 1. Two-Point LOD Scores for Microsatellites in the Candidate Region at
15q22–15q25
Marker
Genetic
Distancea
LOD at v p
Zmax vmax.00 .01 .05 .10 .20 .30 .40
D15S153 62.40 5.43 6.49 6.92 6.65 5.50 3.91 1.99 6.92 .05
D15S988 66.90 .93 1.67 2.09 2.09 1.75 1.22 .55 2.11 .07
D15S216 70.73 7.99 7.86 7.33 6.63 5.13 3.47 1.66 7.99 .00
D15S131 71.28 8.59 8.47 7.96 7.29 5.77 4.04 2.05 8.59 .00
D15S1050 71.82 9.71 9.55 8.90 8.05 6.21 4.18 1.97 9.71 .00
D15S204 71.82 9.24 9.09 8.48 7.69 5.97 4.05 1.91 9.24 .00
D15S188 71.82 7.41 7.29 6.83 6.23 4.92 3.46 1.82 7.41 .00
D15S1023 74.69 3.44 5.18 6.21 6.21 5.30 3.83 1.97 6.28 .07
D15S205 78.92 0.46 1.67 3.33 3.77 3.50 2.60 1.33 3.80 .12
NOTE.—The markers D15S153, D15S131, and D15S205 originate from the ABI Prism Linkage
Mapping Set (MD-10 v2.5, Applied Biosystems). Marker D15S131 generated the highest LOD score
in a total genome scan (data not shown). Recombination events between D15S988 and D15S216
and between D15S188 and D15S1023 defined a candidate region of 7.79 cM. The maximum LOD
score (Zmax) was obtained for D15S1050, as indicated in bold. The NR2E3 gene is located between
D15S1050 and D15S204. LOD score calculations were performed on all available family members.
a According to the Marshfield map (NCBI Map Viewer).
Table 2. Overview of Novel and Known Sequence Changes in NR2E3 Identified in the
Present Study
Nucleotide
Change
Amino Acid
Change
No. of Probands
with Change
Exon or
Intron
Nature
of
Variant
Control
Allele
Frequency ReferenceRP CRD RCD
c.166GrA p.Gly56Arg 3 0 0 Exon 2 M 0 Present study
c.230GrA p.Arg77Gln 0 0 0 Exon 2 UV 1/380 Present study
c.419ArG p.Glu140Gly 2 1 1 Exon 4 P 7/380 Ensembl
c.488TrC p.Met163Thr 2 1 1 Exon 4 P 7/380 Ensembl
c.119–27del16  1 0 0 Intron 1 P 1/380 Haider et al.5
c.119–27dup16  1 0 0 Intron 1 P 0 Present study
c.119–28TrC  4 1 1 Intron 1 P 9/380 Ensembl
NOTE.—CRD, cone-rod dystrophy; RCD, rod-cone dystrophy; M, mutation; UV, unclassified variant; P,
polymorphism. A minus sign () indicates no predicted effect. Numbering of NR2E3 mutations was performed
following HGVS nomenclature guidelines (Ensembl reference sequence ENSP00000317199, with A of
). Of the variants, p.Glu140Gly, p.Met163Thr, and the intronic change c.119-28TrC are knownATGp 1
polymorphisms (Ensembl). One unaffected control person was heterozygous for the novel change c.230GrA
(p.Arg77Gln). Interestingly, this novel missense change is flanking residue Arg76, which has been shown
to be mutated in ESCS (p.Arg76Gln and p.Arg76Trp) (fig. 2A). Although NR2E3 mutations are considered
relatively rare in the general population (frequency estimated to be !1 in 500),9 this change may represent
a recessive NR2E3 mutation rather than a rare polymorphism. No other potentially pathogenic NR2E3 variant
was found in this individual. The novel intronic sequence changes found in patients and controls are
predicted not to affect normal splicing. They are considered polymorphisms.
sition c.166GrA in exon 2 of the NR2E3 gene, which re-
sults in the missense mutation p.Gly56Arg (figs. 1C and
2A) (Ensembl reference sequence ENSP00000317199).
This mutation cosegregated with disease. Subsequently,
NR2E3 was screened in a panel of 86 unrelated probands,
mainly of Belgian origin, with the following potentially
dominant degenerative retinal diseases: rod-cone dystro-
phy (58 probands) including RP (46 probands), cone-rod
dystrophy (22 probands), and cone dystrophy (6 pro-
bands). This led to the identification of the same sequence
change c.166GrA in two additional probands with adRP
(one French, one Belgian) (families F2 and F3) (fig. 1D and
1E). In F2, no additional family members were available
for segregation analysis. The autosomal dominant inher-
itance is evident from the pedigree, however (fig. 1D).
Segregation analysis of c.166GrA was performed in 12
additional affected and 10 unaffected individuals from F3
(fig. 1E). Finally, several known polymorphisms and novel
changes were identified in the test cohort and in a control
group (table 2).
The pathogenic nature of p.Gly56Arg is supported by
the following arguments: (1) cosegregation with disease
in the large adRP-affected families F1 and F3; (2) absence
in 380 control chromosomes; (3) conservation in several
orthologs and paralogs of the nuclear receptor (NR) su-
perfamily (fig. 2B); (4) Polyphen and SIFT predictions, as
well as Grantham score calculation, suggesting that
p.Gly56Arg may affect protein structure or function; (5)
ESEfinder and RESCUE-ESE results predicting the intro-
duction of novel exonic splicing enhancers; and (6)
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Figure 2. A, Theoretical model of the two C4 zinc fingers located in the DBD of NR2E3. The first zinc finger contains the P-box, in
which two or three exposed residues are responsible for half-site sequence recognition. The second zinc finger harbors a dimerization
interface for DBDs (D-box) and is involved in recognition of half-site spacing and mutual orientation. A consensus numbering system,
starting from the first Cys of the first zinc finger, is used for comparison with other NRs in panel B. B, top rows, Alignment of the
human protein sequence of NR2E3 with five orthologs. Middle rows, Three nonhuman NRs belonging to the same subfamily as NR2E3
(dsf, D. melanogaster; fax-1, C. elegans; and photoreceptor-specific like, D. melanogaster). Bottom rows, Human NRs belonging to one
of six NR subfamilies: (1) Thyroid hormone receptor–like (RARa, PPARa, Rev-erba and VDR); (2) HNF4-like (TLX); (3) Estrogen receptor–
like (GR and AR); (4) Nerve Growth factor IB receptor–like (NGFI-B); (5) Fushi tarazu-F1–like (LRH-1); and (6) Germ cell nuclear factor–
like (GCNF1). The official NR nomenclature is given in parentheses.8 Cys residues composing the C4 zinc-finger motif are indicated in
bold. Gly residues in other NRs, corresponding to Gly56 in NR2E3, are indicated in red. Gly56 is conserved in almost all members of
the human NR superfamily and in different orthologs, suggesting a functional constraint. Underlined sequences indicate a nuclear
localization signal (NLS) in VDR and the corresponding putative NLS in NR2E3. The amino acid Ser, in bold, represents Ser74 and Ser51
in NR2E3 and VDR, respectively (details provided in table 3).
Figure 3. Haplotype analysis with intragenic and closely flank-
ing SNPs. The legend is available in its entirety in the online
edition of The American Journal of Human Genetics.
NetPhos 2.0 and NetPhosK 1.0 predictions indicating the
introduction of novel (protein kinase C-specific) phos-
phorylation sites, possibly affecting both function and nu-
clear localization of NR2E3 (table 3).10,11
Two of the three adRP-affected families in which
p.Gly56Arg was found are of Belgian descent (F1 and F3),
and one is French (F2). To assess the origin of p.Gly56Arg,
haplotype analysis was performed using 2 intragenic SNPs,
11 flanking SNPs that are located in a region of 70 kb
around NR2E3, and 1 anonymous microsatellite (at 50 kb
downstream of NR2E3) (HapMap, Ensembl, UCSC Ge-
nome Browser, Primer3). Genotyping of these markers was
performed in core families of F1 and F3 and in the proband
of F2. Interestingly, all affected individuals analyzed in
these three families harbored the same intragenic alleles
and SNPs up to a distance of 7 kb upstream and 35 kb
downstream of NR2E3, respectively. Overall, the maximal
common region between the three families covers ∼75 kb,
suggesting that an ancient founder mutation cannot be
excluded (fig. 3). The identification of p.Gly56Arg in 3
unrelated pedigrees with adRP among 47 families with RP
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Table 4. Clinical Characteristics of
Several Affected Individuals in Families
F1, F2, and F3
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 5. Clinical Characteristics of
Several Affected Individuals in Families
F1, F2, and F3
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
(i.e., 6.4%) may indicate the potential importance of this
mutation in a significant fraction of cases of adRP, at least
in families of European descent. Further studies in larger
cohorts are required to support this hypothesis.
Until now, NR2E3 mutations have been associated only
with autosomal recessive ESCS and related recessive con-
ditions,12 whereas the mutation identified in this study
was found in families with a clinical diagnosis of adRP. In
ESCS, a gain of function of S-cones and a maldevelopment
and/or degeneration of rods lead to an increased sensitiv-
ity to blue light, night blindness, and central visual loss.5
Retinal pigmentation is of the nummular type, typically
located immediately beyond the temporal vascular arcades
and nasal to the optic disc. Electroretinography (ERG) in
ESCS is characterized by severely reduced or absent rod-
mediated responses to a weak light stimulus and by near-
identical responses to a high-intensity stimulus in both
dark- and light-adapted conditions, caused by supernor-
mal S-cone–mediated responses.13,14 Classic adRP is an au-
tosomal dominant rod-cone dystrophy with progressive
degeneration of rods and subsequent involvement of
cones, further characterized by progressive intraretinal
pigment migration, generally of the spicular type. Al-
though the ERG may be initially normal, rod responses
progressively decline over time, with cone-mediated re-
sponses suffering the same fate with some delay in time.1
Ten affected members of F1 and three affected members
of F2 and F3 underwent an extensive ophthalmological
evaluation (clinical details are provided in tables 4 and 5).
Interestingly, the phenotype found in F1, F2, and F3 cor-
responds to classic adRP but also shares some specific char-
acteristics with ESCS. Patients showed a decline of cone
function relatively late, at a time when rod function was
already undetectable (fig. 4). In addition, the phenotype
is characterized by three concentric rings of hyperautoflu-
orescence: around the fovea, along the vascular arcades,
and in the far periphery. Notably, the two more central
rings are located in the same areas as those affected in
ESCS.14 Moreover, the rather limited intraretinal pigmen-
tation seen in the later stages, is of the mixed nummular
and spicular type. In patients without any pigmentation,
nummular areas of hypoautofluorescence around the vas-
cular arcades are reminiscent of the pigment clumps ob-
served in ESCS (fig. 5). As is often seen in adRP, the phe-
notype in F1 is rather variable from one patient to another
(fig. 5 and tables 4 and 5).
Importantly, the phenotypic findings observed in F1,
F2, and F3 represent a novel recognizable clinical subtype
of adRP. Further screening of additional families may pro-
vide more evidence of a robust genotype-phenotype cor-
relation. Genotype-phenotype correlations become more
important in directing molecular testing in adRP, because
of extreme locus heterogeneity. Our findings add to a
slowly growing list of phenotypically recognizable features
relating to underlying adRP genes, such as nonpenetrance
(PRPF31 mutations)15 and clumped pigment deposits (NRL
mutations).16
In addition to phenotypic differences, the RP phenotype
described here and ESCS have a different inheritance pat-
tern. This is comparable with inheritance of conditions
caused by mutations in CRX and NRL, encoding two other
key players of the retinal transcriptional network (RetNet)
(fig. 6). Moreover, individuals with adRP resulting from a
particular NRL mutation (p.Ser50Thr)16 have features rem-
iniscent of the NR2E3-related adRP phenotype found in
our families: mixed spicular-nummular intraretinal pig-
mentation and hyperautofluorescence surrounding the fo-
vea in younger individuals. In addition, recessive muta-
tions in both NR2E3 and NRL also result in comparable
phenotypes.14,24 Indeed, such similarities are not surpris-
ing, because NRL activates transcription of NR2E3 (fig. 6).
In general, adRP and ESCS may have a different path-
ogenesis that is mainly related to the pathophysiology of
the patients’ S-cone photoreceptors. This is reflected by
their typical ERG patterns, which reveal a difference in S-
cone response.1,13 We presume this may be attributed to
the dual regulatory role of NR2E3 and its relation with
other key players of the retinal transcriptional network.
During rod development, NR2E3 has two distinct func-
tions: (1) it suppresses the transcription of cone-specific
genes and (2) it enhances transcriptional activation of rod-
specific genes in concert with other transcription factors
(TFs) such as NR1D1, CRX, and NRL (fig. 6).6,7,17,22 Because
of this dual function, we hypothesize that the predomi-
nant degeneration of rods in adRP in this study results
from a loss of activation of rod-specific genes, whereas the
increased S-cone density and the degeneration of rods in
ESCS are due to a derepression of cone-specific genes and
to a loss of activation of rod-specific genes, respectively
(fig. 6).7,17 Since S-cone function is not enhanced in adRP,
this would imply that p.Gly56Arg, either exclusively or
predominantly, affects the transactivation function of
NR2E3.
We hypothesize that the specific location of NR2E3 mu-
tations may be an important factor in determining their
functional effect. NR2E3 is part of the NR superfamily, in
which the DNA-binding and ligand-binding domains
(DBD and LBD, respectively) are most conserved (fig. 2A).25
ESCS-causing missense mutations in the LBD of NR2E3
have been shown to lead to derepression of cone-specific
www.ajhg.org The American Journal of Human Genetics Volume 81 July 2007 153
Figure 4. Full-field flash ERG. A, ERG traces of patient IV:24 of F1 at age 13 years. Scotopic (dark-adapted) rod-specific responses
are completely absent, whereas scotopic maximal combined rod-cone responses are derived only from cones; amplitudes of photopic
(light-adapted) transient and 30-Hz flicker cone-specific responses are moderately reduced, with limited latency delays; aspects of
scotopic maximal combined rod-cone responses and photopic cone-specific responses to a transient flash are not identical. B, ERG
traces of patient III:15 of F1 at age 62 years. All responses are absent, illustrating that gross retinal function is unmeasurable. C,
Normal traces, for comparison. All ERGs are according to standards of International Society for Clinical Electrophysiology of Vision
(ISCEV). RE, right eye; LE, left eye; mV/div, microvolts per division.
genes, whereas missense mutations in the DBD in ESCS,
affect both transactivation of rhodopsin and derepression
of cone-specific genes.7,22
On the basis of alignment of NR2E3 with other NRs,
p.Gly56Arg is most likely to be located in the DBD (fig.
2B), more specifically in a region between the second and
third cysteine of the first zinc finger of NR2E3, where no
mutations have yet been identified (fig. 2A). The potential
functional importance of Gly56 is sustained by the effect
of natural missense mutations affecting corresponding
residues in other NRs, namely p.Gly30Asp in the vitamin
D receptor (VDR [MIM 601769])26,27 and both p.Gly568Trp
and p.Gly568Val in the androgen receptor (AR [MIM
313700]) (fig. 2B).28,29 They cause autosomal recessive
hypocalcemic 1.25-dihydroxyvitamin D-resistant rickets
(HVDRR [MIM 277440]) and X-linked recessive partial an-
drogen insensitivity syndrome (AIS [MIM 300068]), re-
spectively. Their occurrence suggests that this Gly residue
is prone to mutations, which is in agreement with the
conclusions of this study.
VDRs with p.Gly30Asp display normal ligand binding
but show low affinity for DNA and are transcriptionally
inactive.26,27,30 Weak DNA binding and reduced transacti-
vation is also seen with mutation p.Gly568Val in the AR,
but some normal transrepression functions are still main-
tained.31 This observation, together with an impaired
coactivator binding, suggests that, besides DNA binding,
cross-talk with other proteins may be an essential function
of this Gly residue.32 Involvement in specific protein-pro-
tein interactions is also supported by reporter gene assays
with p.Gly568Trp in the AR, showing that the Gly568
residue is probably more important for transrepression
than for transactivation.33 In addition, the GlyrVal mu-
tation has been studied in the mouse glucocorticoid re-
ceptor (GR [MIM 138040]), where it induces alterations in
affinity and/or transcriptional activation in a promotor-
dependent manner.34
Thus, from these studies, it can be deduced that the
corresponding Gly56 in NR2E3 may play an important
role in DNA binding, promotor-specific transcriptional
activation and/or repression, or specific protein-protein
interactions. The absence of potential NR2E3 consensus
target sequences in the minimal rhodopsin promoter6
suggests a mechanism of action independent of DNA
binding, however, and consequently suggests a major role
for protein-protein interactions. We hypothesize that
NR2E3 mutations causing ESCS affect protein interac-
tions involved in transrepression and/or transactivation,
whereas NR2E3 mutations causing adRP predominantly
affect those that lead to transactivation of rod-specific
genes. More specifically, the Gly56 residue may play an
important role in determining interactions between the
Figure 5. Clinical characteristics of affected members of F1 and F3, revealing a novel NR2E3-related clinical subtype of adRP. A, Late-
stage phenotype in patient III:15 of F1 at age 62 years; composite autofluorescence (AF) (left) and composite fundus (right) of right
eye (RE). Note small, relatively well-preserved macular area on fundus picture—although bull’s-eye pattern of hyperautofluorescence
can be seen on AF in that area, with two hyperfluorescent rings that have virtually merged into one; also note severe narrowing of
retinal vasculature. B, Early-stage phenotype in patient IV:24 of F1 at age 13 years; composite of AF (top) and fundus (bottom left)
and late-phase fluorescein angiography (FA) of posterior pole of RE. Note the presence of two hyperautofluorescent rings on AF: one
in bull’s-eye pattern around the fovea, another in midperiphery beyond temporal vascular arcades and nasal to optic disc (OD). Also
note diffuse chorioretinal atrophy in areas corresponding to hyperautofluorescent rings visible on fundus and angiography picture. The
small darker spot above the superior temporal vascular arcade on AF corresponds to a small retinal hemorrhage unrelated to RP phenotype.
Discrete narrowing of retinal vasculature is also shown. C, Midstage phenotype in patient IV:23 of F1 at age 31 years. Composite AF
(left) and composite fundus pictures (right) of posterior pole of left eye (LE) shows a bull’s-eye pattern with one small, discrete,
intensely hyperautofluorescent ring around the fovea and a second, more diffusely hyperautofluorescent ring within area of temporal
vascular arcades. Also note nummular areas of hypoautofluorescence above temporal vascular arcade, corresponding to areas of outer
retinal atrophy; a dark string-like opacity superotemporal between vascular arcades which corresponds to a floater; marked attenuation
of retinal vasculature; choroidal vasculature shining through due to diffuse chorioretinal atrophy, without intraretinal pigmentation;
and a good-quality fovea. D, Midstage phenotype in patient IV:9 of F3. Clockwise from right, composite infrared image (IR) of fundus
of RE, late phase FA and fundus picture of posterior pole, and optical coherence tomography (OCT) of central macular area of RE at
age 16 years. Note cystic degeneration of fovea on IR, fundus picture, and OCT, without progressive fluorescein diffusion (leakage),
unlike cystic macular edema, on FA, but identical to cystic degeneration seen in ESCS. IR further shows two whiter concentric rings in
bull’s-eye pattern around the fovea, with the larger ring located just inside the temporal vascular arcades; also note sparse spicular
pigmentation in inferior periphery and mild attenuation of retinal vasculature. E, Midstage phenotype in patient IV:19 of F1 at age 29
years; composite AF of RE. Note three concentric rings around posterior pole: one in a bull’s-eye pattern around fovea, a second at
level of temporal vascular arcades and nasal to OD, and a third in periphery (only depicted inferiorly); hypoautofluorescence due to
outer retinal degeneration beyond the peripheral hyperautofluorescent ring; and moderate vascular attenuation.
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Figure 6. Role of retinal TFs during photoreceptor development. Several TFs are required to determine a specific photoreceptor cell
type (rod or cone). First, multipotent retinal progenitor cells (RPC) pass through different stages of competence, finally becoming
postmitotic cells (PMC). The expression of CRX commits a population of PMCs toward photoreceptor lineage.17 A pool of these are
directed to cone fate. It is presumed that cone precursors follow an S-cone default pathway (influenced by CRX and RORb18,19) and that
subsequent L- and M-cone induction is mediated by additional TFs. One of these is Trb2, inducing M-opsin expression but repressing
S-opsin expression, probably as a heterodimer with the nuclear receptor RXRg.20,21 Later in development, another pool of PMCs will
acquire the rod fate by NRL expression. NRL activates transcription of NR2E3, having a positive synergistic influence with CRX, NR1D1,
and NRL on the transcription of rod-specific genes.6,7 Moreover, NR2E3 contributes to rodlike morphology.17 Importantly, rod precursors
are relatively “plastic,” because they are still capable of developing S-cones. NRL and especially NR2E3 are able to repress transcription
of cone-specific genes, to stabilize the rod fate before further development of rodlike characteristics.7,19,22 This dual function of NR2E3,
involving both transrepression of cone-specific genes and transactivation of rod-specific genes, may underlie molecular pathogenesis
of distinct NR2E3-related retinal dystrophies, as illustrated in this study. We hypothesize that mutations affecting both functions lead
to an increased density of S-cones and a degeneration of rods, as seen in ESCS, whereas mutations affecting only or predominantly
the transactivation function result in a predominant degeneration of rods, as seen in adRP. Recent studies have suggested that temporal
differences exist between those NR2E3 functions. NR2E3 expression has been shown in mitotic as well as postmitotic cells of the
developing retina.23,35 Moreover, NR2E3 expression was also seen in both rods and cones of the mature retina. It is presumed that in
postmitotic rods NR2E3 influences rod cell differentiation, whereas, in late mitotic progenitors, its primary function is to suppress the
cone-generation program.35
DBD of NR2E3 and proteins favoring the transactivation
function.
TFs that interact with NR2E3 during transactivation of
rod-specific genes are CRX and NR1D1 (fig. 6). They form
a multiprotein complex with NRL in the retina (fig. 6).6,7
A recent in vivo study showed that NR2E3 can suppress
expression of cone genes and activate expression of rho-
dopsin autonomously but also that it requires coexpres-
sion of NRL during the activation of other rod-specific
genes (fig. 6).17
In summary, p.Gly56Arg may predominantly influence
the terminal differentiation and maintenance of rods
through disruption of the transactivation function of
NR2E3—but not, or only to a minimal extent, of the trans-
repression function—possibly through loss of interactions
with CRX, NRL, or other cofactors. Although it is not yet
clear whether this mutation leads to loss of function, gain
of function, or a dominant-negative effect, any change in
transactivation function of NR2E3 may lead to an imbal-
ance in the dosage-sensitive retinal transcription network,
with subsequent rod degeneration, as is seen in adRP (fig.
6).
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In conclusion, this study provides evidence for a poten-
tially important role of NR2E3 in the causation of adRP.
We propose a different pathogenetic mechanism for the
distinct dominant and recessive NR2E3-related pheno-
types that may be attributed to the dual role of NR2E3 in
the regulation of photoreceptor-specific genes. In addi-
tion, a novel recognizable clinical subtype of adRP is iden-
tified, pointing to NR2E3 mutations and thus serving as
a clinical marker improving targeted molecular genetic
testing in adRP. Further molecular screening of NR2E3 and
phenotypic characterization of a larger cohort of families
with adRP will be performed to corroborate our findings.
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